No | Strategy | Developer (s) | Current status |
---|---|---|---|
1 | Live attenuated yellow fever 17D/DENV chimeric vaccine | Sanofi-Pasteur | Phase 3 trials with a tetravalent formulation in DENV endemic countries |
2 | PDK cell-passaged, live attenuated vaccine | WRAIR/GSK | Phase 2 trials with a tetravalent formulation in endemic countries |
3 | Live attenuated DENV Delta-30 mutation and intertypic DENV chimeric vaccines | NIH/Johns Hopkins | Phase 1/2 trials with monovalent formulations completed; tetravalent |
phase 1 initiated | |||
4 | Dengue prM-E DNA vaccine | NMRC | Phase 1 with monovalent vaccine completed |
5 | Recombinant 80Â % E subunit antigen vaccine | Hawaii Biotech/Merck | Phase 1 with monovalent vaccine initiated |
6 | Purified inactivated vaccine | WRAIR | Phase 1 with monovalent vaccine initiated |
7 | Live attenuated chimeric DENV vaccine | CDC | Phase 1 with monovalent vaccine initiated |